This funding opportunity supports studies aimed at elucidating therapeutic effects and addressing methodological challenges in clinical trials of rapid-acting psychotropic interventional drugs (RAPIDs). It encourages research to enhance trial design rigor, improve data interpretability, and advance understanding of optimal delivery and sustainability of RAPIDs and adjunctive psychosocial interventions.
Eligible applicants include public and private institutions of higher education, nonprofits, tribal organizations, government entities, small businesses, and for-profit organizations other than small businesses. Foreign organizations and non-domestic components are not eligible.
